A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
| Title: | A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial |
|---|---|
| Authors: | Pujol, Jean-Louis, Greillier, Laurent, Audigier-Valette, Clarisse, Moro-Sibilot, Denis, Uwer, Lionel, Hureaux, José, Guisier, Florian, Carmier, Delphine, Madelaine, Jeannick, Otto, Josiane, Gounant, Valérie, Merle, Patrick, Mourlanette, Pierre, Molinier, Olivier, Renault, Aldo, Rabeau, Audrey, Antoine, Martine, Denis, Marc G., Bommart, Sebastien, Langlais, Alexandra, Morin, Franck, Souquet, Pierre-Jean |
| Source: | In Journal of Thoracic Oncology May 2019 14(5):903-913 |
| Database: | ScienceDirect |
Be the first to leave a comment!